Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards
Identifieur interne : 006931 ( Main/Exploration ); précédent : 006930; suivant : 006932Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards
Auteurs : S. Vasikaran [Australie] ; R. Eastell [Royaume-Uni] ; O. Bruyere [Belgique] ; A. J. Foldes [Israël] ; P. Garnero [France] ; A. Griesmacher [Autriche] ; M. Mcclung [États-Unis] ; H. A. Morris [Australie] ; S. Silverman [États-Unis] ; T. Trenti [Italie] ; D. A. Wahl [Suisse] ; C. Cooper [Royaume-Uni] ; J. A. Kanis [Royaume-Uni]Source :
- Osteoporosis international [ 0937-941X ] ; 2011.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Summary The International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) recommend that a marker of bone formation (serum procollagen type I N propeptide, s-PINP) and a marker of bone resorption (serum C-terminal telopeptide of type I collagen, s-CTX) are used as reference analytes for bone turnover markers in clinical studies. Introduction Bone turnover markers (BTM) predict fracture risk, and treatment-induced changes in specific markers account for a substantial proportion of fracture risk reduction. The aims of this report were to determine their clinical potential in the prediction of fracture risk and for monitoring the treatment of osteoporosis and to set an appropriate research agenda. Methods Evidence from prospective studies was gathered through literature review of the PUBMED database between the years 2000 and 2010 and the systematic review of the Agency for Healthcare Research and Quality up to 2001. Results High levels of BTMs may predict fracture risk independently from bone mineral density in postmenopausal women. They have been used for this purpose in clinical practice for many years, but there is still a need for stronger evidence on which to base practice. BTMs provide pharmacodynamic information on the response to osteoporosis treatment, and as a result, they are widely used for monitoring treatment in the individual. However, their clinical value for monitoring is limited by inadequate appreciation of the sources of variability, by limited data for comparison of treatments using the same BTM and by inadequate quality control. IOF/IFCC recommend one bone formation marker (s-PINP) and one bone resorption marker (s-CTX) to be used as reference markers and measured by standardised assays in observational and intervention studies in order to compare the performance of alternatives and to enlarge the international experience of the application of markers to clinical medicine. Conclusion BTM hold promise in fracture risk prediction and for monitoring treatment. Uncertainties over their clinical use can be in part resolved by adopting international reference standards.
Affiliations:
- Australie, Autriche, Belgique, France, Israël, Italie, Royaume-Uni, Suisse, États-Unis
- Angleterre, Auvergne-Rhône-Alpes, Oxfordshire, Province de Liège, Rhône-Alpes, Région wallonne
- Liège, Lyon, Oxford
- Université d'Oxford, Université de Liège
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 001F89
- to stream PascalFrancis, to step Curation: 003F45
- to stream PascalFrancis, to step Checkpoint: 001908
- to stream Main, to step Merge: 006D59
- to stream Main, to step Curation: 006931
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards</title><author><name sortKey="Vasikaran, S" sort="Vasikaran, S" uniqKey="Vasikaran S" first="S." last="Vasikaran">S. Vasikaran</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Core Clinical Pathology and Biochemistry, Path West Laboratory Medicine, Royal Perth Hospital</s1><s2>Perth, WA</s2><s3>AUS</s3><sZ>1 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Perth, WA</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>School of Pathology and Laboratory Medicine, University of Western Australia</s1><s2>Nedlands, WA</s2><s3>AUS</s3><sZ>1 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Nedlands, WA</wicri:noRegion></affiliation></author><author><name sortKey="Eastell, R" sort="Eastell, R" uniqKey="Eastell R" first="R." last="Eastell">R. Eastell</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Centre for Biomedical Research, Northern General Hospital, Herries Road, Sheffield, South Yorkshire</s1><s2>England S5 7AU</s2><s3>GBR</s3><sZ>2 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>England S5 7AU</wicri:noRegion></affiliation></author><author><name sortKey="Bruyere, O" sort="Bruyere, O" uniqKey="Bruyere O" first="O." last="Bruyere">O. Bruyere</name><affiliation wicri:level="4"><inist:fA14 i1="04"><s1>Department of Public Health, Epidemiology and Health Economics, University of Liège</s1><s2>Liège</s2><s3>BEL</s3><sZ>3 aut.</sZ></inist:fA14><country>Belgique</country><placeName><settlement type="city">Liège</settlement><region type="region" nuts="1">Région wallonne</region><region type="province" nuts="1">Province de Liège</region></placeName><orgName type="university">Université de Liège</orgName></affiliation></author><author><name sortKey="Foldes, A J" sort="Foldes, A J" uniqKey="Foldes A" first="A. J." last="Foldes">A. J. Foldes</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Osteoporosis Center, Hadassah University Hospital, Mount Scopus</s1><s2>Jerusalem 91240</s2><s3>ISR</s3><sZ>4 aut.</sZ></inist:fA14><country>Israël</country><wicri:noRegion>Jerusalem 91240</wicri:noRegion></affiliation></author><author><name sortKey="Garnero, P" sort="Garnero, P" uniqKey="Garnero P" first="P." last="Garnero">P. Garnero</name><affiliation wicri:level="3"><inist:fA14 i1="06"><s1>INSERM Unit 664</s1><s2>Lyon</s2><s3>FRA</s3><sZ>5 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Griesmacher, A" sort="Griesmacher, A" uniqKey="Griesmacher A" first="A." last="Griesmacher">A. Griesmacher</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Central Institute of Medical and Chemical Laboratory Diagnostics, University Hospital of Innsbruck</s1><s2>6080, Innsbruck</s2><s3>AUT</s3><sZ>6 aut.</sZ></inist:fA14><country>Autriche</country><wicri:noRegion>6080, Innsbruck</wicri:noRegion></affiliation></author><author><name sortKey="Mcclung, M" sort="Mcclung, M" uniqKey="Mcclung M" first="M." last="Mcclung">M. Mcclung</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Oregon Osteoporosis Center, 5050 NE Hoyt Street, Suite 651</s1><s2>Portland, OR 97213</s2><s3>USA</s3><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Portland, OR 97213</wicri:noRegion></affiliation></author><author><name sortKey="Morris, H A" sort="Morris, H A" uniqKey="Morris H" first="H. A." last="Morris">H. A. Morris</name><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>School of Pharmacy and Medical Sciences, University of South Australia</s1><s2>Adelaide, SA 5000</s2><s3>AUS</s3><sZ>8 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Adelaide, SA 5000</wicri:noRegion></affiliation></author><author><name sortKey="Silverman, S" sort="Silverman, S" uniqKey="Silverman S" first="S." last="Silverman">S. Silverman</name><affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Cedars-Sinai/University of California</s1><s2>Los Angeles, CA</s2><s3>USA</s3><sZ>9 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Cedars-Sinai/University of California</wicri:noRegion></affiliation></author><author><name sortKey="Trenti, T" sort="Trenti, T" uniqKey="Trenti T" first="T." last="Trenti">T. Trenti</name><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Patologia Clinica, Tossicologia e Diagnostica Avanzata, Dipartimento di Patologia Clinica, Ospedale Nuovo Sant'Agostino Estense, via Giardini 1355</s1><s2>4110, Modena</s2><s3>ITA</s3><sZ>10 aut.</sZ></inist:fA14><country>Italie</country><wicri:noRegion>4110, Modena</wicri:noRegion></affiliation></author><author><name sortKey="Wahl, D A" sort="Wahl, D A" uniqKey="Wahl D" first="D. A." last="Wahl">D. A. Wahl</name><affiliation wicri:level="1"><inist:fA14 i1="12"><s1>International Osteoporosis Foundation</s1><s2>Nyon</s2><s3>CHE</s3><sZ>11 aut.</sZ></inist:fA14><country>Suisse</country><wicri:noRegion>International Osteoporosis Foundation</wicri:noRegion></affiliation></author><author><name sortKey="Cooper, C" sort="Cooper, C" uniqKey="Cooper C" first="C." last="Cooper">C. Cooper</name><affiliation wicri:level="4"><inist:fA14 i1="13"><s1>NIHR Musculoskeletal Biomedical Research Unit, Institute of Musculoskeletal Sciences, University of Oxford</s1><s2>Oxford OX3 7LD</s2><s3>GBR</s3><sZ>12 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Oxford</settlement><region type="nation">Angleterre</region><region type="région" nuts="1">Oxfordshire</region></placeName><orgName type="university">Université d'Oxford</orgName></affiliation></author><author><name sortKey="Kanis, J A" sort="Kanis, J A" uniqKey="Kanis J" first="J. A." last="Kanis">J. A. Kanis</name><affiliation wicri:level="1"><inist:fA14 i1="14"><s1>Centre for Metabolic Bone Diseases (WHO Collaborating Centre), University of Sheffield Medical School, Beech Hill Road</s1><s2>Sheffield S10 2RX</s2><s3>GBR</s3><sZ>13 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>Sheffield S10 2RX</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">11-0116213</idno><date when="2011">2011</date><idno type="stanalyst">PASCAL 11-0116213 INIST</idno><idno type="RBID">Pascal:11-0116213</idno><idno type="wicri:Area/PascalFrancis/Corpus">001F89</idno><idno type="wicri:Area/PascalFrancis/Curation">003F45</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001908</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001908</idno><idno type="wicri:doubleKey">0937-941X:2011:Vasikaran S:markers:of:bone</idno><idno type="wicri:Area/Main/Merge">006D59</idno><idno type="wicri:Area/Main/Curation">006931</idno><idno type="wicri:Area/Main/Exploration">006931</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards</title><author><name sortKey="Vasikaran, S" sort="Vasikaran, S" uniqKey="Vasikaran S" first="S." last="Vasikaran">S. Vasikaran</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Core Clinical Pathology and Biochemistry, Path West Laboratory Medicine, Royal Perth Hospital</s1><s2>Perth, WA</s2><s3>AUS</s3><sZ>1 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Perth, WA</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>School of Pathology and Laboratory Medicine, University of Western Australia</s1><s2>Nedlands, WA</s2><s3>AUS</s3><sZ>1 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Nedlands, WA</wicri:noRegion></affiliation></author><author><name sortKey="Eastell, R" sort="Eastell, R" uniqKey="Eastell R" first="R." last="Eastell">R. Eastell</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Centre for Biomedical Research, Northern General Hospital, Herries Road, Sheffield, South Yorkshire</s1><s2>England S5 7AU</s2><s3>GBR</s3><sZ>2 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>England S5 7AU</wicri:noRegion></affiliation></author><author><name sortKey="Bruyere, O" sort="Bruyere, O" uniqKey="Bruyere O" first="O." last="Bruyere">O. Bruyere</name><affiliation wicri:level="4"><inist:fA14 i1="04"><s1>Department of Public Health, Epidemiology and Health Economics, University of Liège</s1><s2>Liège</s2><s3>BEL</s3><sZ>3 aut.</sZ></inist:fA14><country>Belgique</country><placeName><settlement type="city">Liège</settlement><region type="region" nuts="1">Région wallonne</region><region type="province" nuts="1">Province de Liège</region></placeName><orgName type="university">Université de Liège</orgName></affiliation></author><author><name sortKey="Foldes, A J" sort="Foldes, A J" uniqKey="Foldes A" first="A. J." last="Foldes">A. J. Foldes</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Osteoporosis Center, Hadassah University Hospital, Mount Scopus</s1><s2>Jerusalem 91240</s2><s3>ISR</s3><sZ>4 aut.</sZ></inist:fA14><country>Israël</country><wicri:noRegion>Jerusalem 91240</wicri:noRegion></affiliation></author><author><name sortKey="Garnero, P" sort="Garnero, P" uniqKey="Garnero P" first="P." last="Garnero">P. Garnero</name><affiliation wicri:level="3"><inist:fA14 i1="06"><s1>INSERM Unit 664</s1><s2>Lyon</s2><s3>FRA</s3><sZ>5 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Griesmacher, A" sort="Griesmacher, A" uniqKey="Griesmacher A" first="A." last="Griesmacher">A. Griesmacher</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Central Institute of Medical and Chemical Laboratory Diagnostics, University Hospital of Innsbruck</s1><s2>6080, Innsbruck</s2><s3>AUT</s3><sZ>6 aut.</sZ></inist:fA14><country>Autriche</country><wicri:noRegion>6080, Innsbruck</wicri:noRegion></affiliation></author><author><name sortKey="Mcclung, M" sort="Mcclung, M" uniqKey="Mcclung M" first="M." last="Mcclung">M. Mcclung</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Oregon Osteoporosis Center, 5050 NE Hoyt Street, Suite 651</s1><s2>Portland, OR 97213</s2><s3>USA</s3><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Portland, OR 97213</wicri:noRegion></affiliation></author><author><name sortKey="Morris, H A" sort="Morris, H A" uniqKey="Morris H" first="H. A." last="Morris">H. A. Morris</name><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>School of Pharmacy and Medical Sciences, University of South Australia</s1><s2>Adelaide, SA 5000</s2><s3>AUS</s3><sZ>8 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Adelaide, SA 5000</wicri:noRegion></affiliation></author><author><name sortKey="Silverman, S" sort="Silverman, S" uniqKey="Silverman S" first="S." last="Silverman">S. Silverman</name><affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Cedars-Sinai/University of California</s1><s2>Los Angeles, CA</s2><s3>USA</s3><sZ>9 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Cedars-Sinai/University of California</wicri:noRegion></affiliation></author><author><name sortKey="Trenti, T" sort="Trenti, T" uniqKey="Trenti T" first="T." last="Trenti">T. Trenti</name><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Patologia Clinica, Tossicologia e Diagnostica Avanzata, Dipartimento di Patologia Clinica, Ospedale Nuovo Sant'Agostino Estense, via Giardini 1355</s1><s2>4110, Modena</s2><s3>ITA</s3><sZ>10 aut.</sZ></inist:fA14><country>Italie</country><wicri:noRegion>4110, Modena</wicri:noRegion></affiliation></author><author><name sortKey="Wahl, D A" sort="Wahl, D A" uniqKey="Wahl D" first="D. A." last="Wahl">D. A. Wahl</name><affiliation wicri:level="1"><inist:fA14 i1="12"><s1>International Osteoporosis Foundation</s1><s2>Nyon</s2><s3>CHE</s3><sZ>11 aut.</sZ></inist:fA14><country>Suisse</country><wicri:noRegion>International Osteoporosis Foundation</wicri:noRegion></affiliation></author><author><name sortKey="Cooper, C" sort="Cooper, C" uniqKey="Cooper C" first="C." last="Cooper">C. Cooper</name><affiliation wicri:level="4"><inist:fA14 i1="13"><s1>NIHR Musculoskeletal Biomedical Research Unit, Institute of Musculoskeletal Sciences, University of Oxford</s1><s2>Oxford OX3 7LD</s2><s3>GBR</s3><sZ>12 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Oxford</settlement><region type="nation">Angleterre</region><region type="région" nuts="1">Oxfordshire</region></placeName><orgName type="university">Université d'Oxford</orgName></affiliation></author><author><name sortKey="Kanis, J A" sort="Kanis, J A" uniqKey="Kanis J" first="J. A." last="Kanis">J. A. Kanis</name><affiliation wicri:level="1"><inist:fA14 i1="14"><s1>Centre for Metabolic Bone Diseases (WHO Collaborating Centre), University of Sheffield Medical School, Beech Hill Road</s1><s2>Sheffield S10 2RX</s2><s3>GBR</s3><sZ>13 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>Sheffield S10 2RX</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Osteoporosis international</title><title level="j" type="abbreviated">Osteoporos. int.</title><idno type="ISSN">0937-941X</idno><imprint><date when="2011">2011</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Osteoporosis international</title><title level="j" type="abbreviated">Osteoporos. int.</title><idno type="ISSN">0937-941X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Bone</term><term>Bone remodeling</term><term>Fracture</term><term>Osteoporosis</term><term>Predictive factor</term><term>Rheumatology</term><term>Risk factor</term><term>Treatment</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Remodelage osseux</term><term>Facteur prédictif</term><term>Fracture</term><term>Facteur risque</term><term>Ostéoporose</term><term>Traitement</term><term>Os</term><term>Rhumatologie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Summary The International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) recommend that a marker of bone formation (serum procollagen type I N propeptide, s-PINP) and a marker of bone resorption (serum C-terminal telopeptide of type I collagen, s-CTX) are used as reference analytes for bone turnover markers in clinical studies. Introduction Bone turnover markers (BTM) predict fracture risk, and treatment-induced changes in specific markers account for a substantial proportion of fracture risk reduction. The aims of this report were to determine their clinical potential in the prediction of fracture risk and for monitoring the treatment of osteoporosis and to set an appropriate research agenda. Methods Evidence from prospective studies was gathered through literature review of the PUBMED database between the years 2000 and 2010 and the systematic review of the Agency for Healthcare Research and Quality up to 2001. Results High levels of BTMs may predict fracture risk independently from bone mineral density in postmenopausal women. They have been used for this purpose in clinical practice for many years, but there is still a need for stronger evidence on which to base practice. BTMs provide pharmacodynamic information on the response to osteoporosis treatment, and as a result, they are widely used for monitoring treatment in the individual. However, their clinical value for monitoring is limited by inadequate appreciation of the sources of variability, by limited data for comparison of treatments using the same BTM and by inadequate quality control. IOF/IFCC recommend one bone formation marker (s-PINP) and one bone resorption marker (s-CTX) to be used as reference markers and measured by standardised assays in observational and intervention studies in order to compare the performance of alternatives and to enlarge the international experience of the application of markers to clinical medicine. Conclusion BTM hold promise in fracture risk prediction and for monitoring treatment. Uncertainties over their clinical use can be in part resolved by adopting international reference standards.</div></front></TEI><affiliations><list><country><li>Australie</li><li>Autriche</li><li>Belgique</li><li>France</li><li>Israël</li><li>Italie</li><li>Royaume-Uni</li><li>Suisse</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Auvergne-Rhône-Alpes</li><li>Oxfordshire</li><li>Province de Liège</li><li>Rhône-Alpes</li><li>Région wallonne</li></region><settlement><li>Liège</li><li>Lyon</li><li>Oxford</li></settlement><orgName><li>Université d'Oxford</li><li>Université de Liège</li></orgName></list><tree><country name="Australie"><noRegion><name sortKey="Vasikaran, S" sort="Vasikaran, S" uniqKey="Vasikaran S" first="S." last="Vasikaran">S. Vasikaran</name></noRegion><name sortKey="Morris, H A" sort="Morris, H A" uniqKey="Morris H" first="H. A." last="Morris">H. A. Morris</name><name sortKey="Vasikaran, S" sort="Vasikaran, S" uniqKey="Vasikaran S" first="S." last="Vasikaran">S. Vasikaran</name></country><country name="Royaume-Uni"><noRegion><name sortKey="Eastell, R" sort="Eastell, R" uniqKey="Eastell R" first="R." last="Eastell">R. Eastell</name></noRegion><name sortKey="Cooper, C" sort="Cooper, C" uniqKey="Cooper C" first="C." last="Cooper">C. Cooper</name><name sortKey="Kanis, J A" sort="Kanis, J A" uniqKey="Kanis J" first="J. A." last="Kanis">J. A. Kanis</name></country><country name="Belgique"><region name="Région wallonne"><name sortKey="Bruyere, O" sort="Bruyere, O" uniqKey="Bruyere O" first="O." last="Bruyere">O. Bruyere</name></region></country><country name="Israël"><noRegion><name sortKey="Foldes, A J" sort="Foldes, A J" uniqKey="Foldes A" first="A. J." last="Foldes">A. J. Foldes</name></noRegion></country><country name="France"><region name="Auvergne-Rhône-Alpes"><name sortKey="Garnero, P" sort="Garnero, P" uniqKey="Garnero P" first="P." last="Garnero">P. Garnero</name></region></country><country name="Autriche"><noRegion><name sortKey="Griesmacher, A" sort="Griesmacher, A" uniqKey="Griesmacher A" first="A." last="Griesmacher">A. Griesmacher</name></noRegion></country><country name="États-Unis"><noRegion><name sortKey="Mcclung, M" sort="Mcclung, M" uniqKey="Mcclung M" first="M." last="Mcclung">M. Mcclung</name></noRegion><name sortKey="Silverman, S" sort="Silverman, S" uniqKey="Silverman S" first="S." last="Silverman">S. Silverman</name></country><country name="Italie"><noRegion><name sortKey="Trenti, T" sort="Trenti, T" uniqKey="Trenti T" first="T." last="Trenti">T. Trenti</name></noRegion></country><country name="Suisse"><noRegion><name sortKey="Wahl, D A" sort="Wahl, D A" uniqKey="Wahl D" first="D. A." last="Wahl">D. A. Wahl</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006931 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 006931 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:11-0116213
|texte= Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards
}}
| This area was generated with Dilib version V0.6.33. |  |